Metacrine Inc

NASDAQ:MTCR   3:59:50 PM EDT
3.79
+0.08 (+2.16%)
5:17:11 PM EDT: $1.98 -1.81 (-47.76%)
Earnings Announcements

Metacrine Reports Q4 2020 Financial Results

Published: 03/18/2021 10:46 GMT
Metacrine Inc (MTCR) - Metacrine - Interim Data From Phase 2a Trial of Met642 in Nash Patients On-track to Be Reported in Q4 of 2021.
Metacrine - Cash, Cash Equivalents & Short-term Investments As of Dec 31, 2020 Will Be Sufficient to Fund Its Current Operating Plan Through 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.